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a b s t r a c t
Liver X receptors (LXRs) are nuclear receptors that act as ligand-dependent transcription factors forming
permissive heterodimers with retinoid X receptors (RXRs). In this study we aimed to assess the effect of
LXR/RXR activation on the transcriptional induction of pro-inﬂammatory genes including cyclooxygenase-2
(COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) in activated macrophages. Our study
shows that LXR ligands such as oxysterols, GW3965 or TO901317, as well as RXR ligands like 9cis retinoic
acid or SR11237, decreased LPS-induced expression of COX-2 and mPGES-1. Consequently, LPS-dependent
PGE2 production was substantially reduced in macrophages treated with LXR/RXR ligands. The inhibitory
effects of LXR/RXR activation on LPS-induced expression of COX-2 and mPGES-1 in macrophages, occurred
by a mechanism involving interference with transcriptional activation of these genes. LXR/RXR activation
interfered with the activity of transcription factors essential in the up-regulation of the expression of pro-
inﬂammatory genes in these cells, such as NFκB, but also Egr-1, which had not been previously associated
with LXR-mediated gene repression. As this transcription factor is involved in the regulation of a variety of
genes involved in inﬂammatory processes, LXR and RXR-mediated interference with Egr-1 signaling could
represent an important event mediating the anti-inﬂammatory effects of these receptors in macrophages.
& 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Liver X receptors (LXRs) belongs to the nuclear receptor family of
ligand-activated transcription factors. There are two isoforms of LXRs
known as LXRα and LXRβ, which share high sequence homology but
differ in localization. While the β isoform is expressed broadly in most
tissues, LXRα is more abundant in some tissues such as liver, adipose
tissue, kidney or macrophages [1]. These nuclear receptors modulate
different metabolic processes by regulating transcription of a variety of
genes. These receptors exert their actions by forming permissive
heterodimers with retinoid X receptors (RXRs). LXR/RXR heterodimers
can be activated by either LXR agonists, as oxysterols or synthetic
ligands such as TO901317 (TO) or GW3965 (GW), or by RXR ligands as
9-cis retinoic acid (9cisRA) [1–4].
LXRs regulate gene expression by two different mechanisms of
action. The best-characterized one is the transactivation mechanism,
through which these nuclear receptors are involved in lipid metabo-
lism regulation by inducing the expression of target genes like ABC-
transporters (ABCA1 and ABCG1) and transcription factors as SREBP-1c,
among others [5–7]. LXRs bind to DNA at speciﬁc sequences deﬁned as
LXR response elements (LXRE) along with corepressor molecules. Upon
activation by ligand binding, the LXR/RXR heterodimers suffer a
conformational change that allows clearance of corepressors and
binding of coactivators such as SRC-1 (steroid receptor co-activator)
and p300 [1,8,9]. In this way, the expression of LXR target genes is
induced, having a variety of effects at different levels of cholesterol
homeostasis in different tissues: induction of reverse cholesterol
transport in macrophages, increase of lipogenesis or cholesterol excre-
tion in liver and reduction of intestinal cholesterol absorption [7,10–13].
Research on the effects of the activation of these nuclear re-
ceptors has gained great relevance since their recent characterization
as integrators of both cholesterol metabolism and inﬂammatory
responses [14–16]. These ﬁndings supported LXR involvement in
cardiovascular pathologies with macrophage activation and altera-
tions in cholesterol homeostasis such as atherosclerosis [17–19].
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Activated LXRs can exert anti-inﬂammatory effects by inducing the
expression of arginase II, which competes for substrate with the
inﬂammatory protein iNOS [20]; Mer, involved in phagocytosis of
apoptotic cells [21]; or AIM (apoptotic inhibitor of macrophages) [22].
These receptors can also act as transcriptional repressors, inhibiting
the expression of a variety of pro-inﬂammatory genes such as COX-2,
interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), indu-
cible nitric oxide synthase (iNOS) or matrix metalloproteinase-9
(MMP-9) [14,23–26]. Different studies have reported that LXR-me-
diated transrepression involves interference with the activity of
transcription factors, as nuclear factor kappa B (NFκB) [14,23,27],
which plays an essential role in inﬂammatory signaling [28,29].
Among the inﬂammatory mediators involved in immune res-
ponses, prostanoids, which include prostaglandins (PGs), prostacyclin
(PGI2) and thromboxane (TX2), are determinant for the progress
but also for the resolution of inﬂammation. Their synthesis takes
place from arachidonic acid metabolism through the action of
cyclooxygenases, mainly COX-2, which is induced by proinﬂammatory
stimuli, and terminal synthases as mPGES-1 in the case of prosta-
glandin E2 (PGE2) production. The regulation of the expression of
these enzymes is essential for the ﬁnal balance of prostaglandin
production and therefore, for the outcome of inﬂammatory responses
and function of immune cells such as macrophages [30,31]. Transcrip-
tion factors as NFκB and Early growth response factor-1 (Egr-1) are
involved in the expression of both COX-2 and mPGES-1 [32–35]. NF-
κB proteins comprise a family of transcription factors that are
involved in the control of different biological processes, including
immune and inﬂammatory responses. Activation of this transcription
factor plays an essential role in a number of diseases, including cancer,
arthritis, chronic inﬂammation, asthma, neurodegenerative diseases,
and heart disease [28,29]. Egr-1 is also crucial for inﬂammatory
signaling, playing a determinant role in the development of inﬂam-
matory pathologies by regulating the expression of a variety of genes
[36,37].
Several aspects of LXR-mediated transrepression are still to be
elucidated in order to fully understand how activation of LXR/RXR
heterodimers can affect inﬂammation under different experimental
or pathological conditions. Here we have focused on the repressive
effects of LXR and RXR agonists on the LPS-induced expression of
COX-2 and mPGES-1 in macrophages. We demonstrate that both LXR
and RXR ligands are able to reduce the induction of both enzymes by
a mechanism that involves interference with transcription factors
such as NFκB, but also Egr-1. We provide new insights into the studies
on the LXR-mediated transrepression mechanisms by demonstrating
the interference of LXR and RXR agonists with the LPS-induced
expression and transcriptional activity of Egr-1. Our results point
out to LXR/RXR mediated inhibition of Egr-1 dependent signaling as
an important event contributing to the anti-inﬂammatory effects of
these receptors in macrophages.
2. Material and methods
2.1. Cell culture and reagents
The mouse macrophage RAW 264.7 and the human THP-1 mono-
cyte cell lines were cultured in RPMI 1640 medium (Invitrogen)
supplemented with 5% fetal calf serum (FCS, BioWhittaker-Lonza),
100 U/ml penicillin, 100 μg/ml streptomycin, 1000 U/ml gentamycin,
2 mM L-glutamine and 0.1 mM non-essential amino acids.
Peritoneal macrophages were obtained from C57BL/6J mice (Harlan
Laboratories) injected with 1 ml thioglycollate (10% w/v, DIFCO) in the
peritoneal cavity as previously described [38]. Brieﬂy, four days post-
injection, cells were obtained by peritoneal lavage with cold PBS,
centrifuged and seeded in culture plates. After 4 h, non-adherent cells
were removed by gentle aspiration and washing with PBS, and
macrophage-adherent cells were maintained in culture with complete
RPMI medium supplemented with 5% FCS. The population of adherent
cells was consistently composed of 480% F4-80þ CD11bþ macro-
phages, as determined by ﬂow cytometry analysis. Cells were stimu-
lated with bacterial lipopolysaccharide (LPS) from Escherichia coli 026:
B6 (2 μg/ml, Sigma-Aldrich) in complete RPMI medium supplemented
with 2% FCS. Treatment of cell cultures with the LXR ligands TO901317
(0.1 to 2.5 μM, Cayman Chemical), GW3965 (0.1 to 2.5 μM, Sigma-
Aldrich) and 25-hydroxycholesterol (1 to 15 μM, Sigma-Aldrich); the
RXR ligands 9cisRA (0.1 to 2.5 μM, Sigma-Aldrich) and SR11237 (0.1 to
2.5 μM, Tocris bioscience), was performed 1 h before LPS-stimulation.
2.2. Plasmid constructs
COX-2 promoter luciferase construct (COX-2-luc, p2-1900) con-
tains the 1796 to þ104 region of the human COX-2 gene cloned in
pXP2 plasmid [39]. Luciferase construct mPGES-1-luc containing the
631 to 1 region of the human mPGES-1 gene cloned into a pGL3
basic plasmid was kindly provided by Sabine Grösch (Institute of
Clinical Pharmacology, Frankfurt, Germany) [40]. Egr1-luc (Egr1-
Pro36-luc) containing two binding sites for Egr-1 inserted upstream
of a prolactin minimal promoter was generously provided by Dr. Ana
Pérez-Castillo (Instituto de Investigaciones Biomédicas, Madrid,
Spain) [41]. NFκB-luc (pNF3ConA-luc) contains three copies of the
consensus κB sequence from the immunoglobulin κ chain upstream
of a conalbuminminimal promoter and was kindly provided by Dr. F.
Arenzana-Seisdedos (Institute Pasteur, Paris, France) [42]. LXRE-luc
(pTK-3 LXRE-luc) contains three consensus binding sites for LXR
upstream of a thymidine kinase promoter and was kindly provided
by Dr. A. Castrillo (Instituto de Investigaciones Biomédicas, Madrid,
Spain) [20]. RXRE-luc reporter (pTK-CRBPII-luc) vector including
5 copies of the RXRE of the CRBPII gene as well as human LXRα
(pCMX-hLXRα) and mouse RXRα (pCMX-mRXRα) expression vec-
tors were a kind gift from Dr. D. J. Mangelsdorf (Howard Hughes
Medical Institute, California, US) [43].
2.3. Transfection and luciferase assays
Transcriptional activity of different luciferase reporter constructs
was analyzed by luciferase reporter gene assays. Brieﬂy, THP-1 cells
were transiently transfected with 0.7 to 1 μg of the different con-
structs using 2.25 μl of the Jetprime reagent (Polyplus Transfection)
diluted in RPMI without antibiotics and supplemented with 0.5%
FCS. After 4 h of transfection, cultures were treated with the
indicated stimuli. Then, cells were harvested and lysed, and lucifer-
ase activity was determined by using a luciferase assay kit (Promega)
in a luminometer Monolight 2010 (Analytical Luminescence Labora-
tory, San Diego, CA). Transfection experiments were performed in
triplicate and normalized by mg of protein. Results are expressed as
fold induction7SD (RLUs per mg of protein in the experimental
samples/RLUs per mg of protein in the experimental controls).
2.4. mRNA analysis
Total RNA was isolated using the “Absolutely RNA miniprep kit”
(Stratagene) and reverse transcribed into cDNA by the “RNA PCR
core kit” (Perkin-Elmer). For standard RT-PCR, cDNA was used for
PCR ampliﬁcation with speciﬁc primers for human ABCA1, sense
50-CTCAGAGGTGGCTCTGATGAC-30 and antisense 50-GTGATTGACCAC
CCATACAGCAA-30; ABCG1 sense 50-CGCATCTCACTGTGCAGGAG-30
and antisense 50-CAAAGAAAAGGGTTCACCTCG-30; and GAPDH, sense
50-CCACCCATGGCAAATTCCATGGCA-30 and antisense 50-TCTAGACG
GCAGGTCAGGTCCACC-30 . PCR reactions were ampliﬁed by 25 to 30
cycles of denaturation at 94 1C for 45 s, annealing at 55 or 60 1C
for 45 s, and extension at 72 1C for 45 s. Ampliﬁed cDNAs were
separated by agarose gel electrophoresis and bands visualized by
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ethidium bromide staining. Data shown correspond to a number of
cycles where the amount of ampliﬁed product is proportional to the
abundance of starting material.
For quantitative real-time RT-PCR analysis, total RNA was reversed
transcribed using the components of the “High Capacity cDNA Archive
Kit” (Applied Biosystems). Ampliﬁcation of the cDNAs was performed
using the TaqMan Universal PCR Master Mix (Applied Biosystems) on
an ABI PRISM 7900HT instrument (Applied Biosystems) for 40 cycles
with speciﬁc primers and Taqman probes (Applied Biosystems). All
samples were run in triplicate and normalized by the expression of the
endogenous 18S gene. Quantiﬁcation of gene expression by real-time
RT-PCR was calculated by the comparative threshold cycle (ΔΔCT)
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Fig. 1. LXR ligands induce LXRE-dependent transactivation in macrophages. (A) RAW264.7 and THP-1 cells transfected with the reporter vector LXRE-luc. (B) RAW264.7 cells
co-transfected with the plasmid LXRE-luc and expression vectors for LXRα, RXRα or an empty vector (pcDNA3). After transfection, cells were treated with LXR ligands
TO901317 (TO) or GW3965 (GW) at 1 μM or 25-hidroxycholesterol (25HC) at 10 μM and/or the RXR ligand 9cisRA (1 μM) for 18 h and then luciferase activity was measured in
cellular extracts. Results of a representative experiment of the four performed are shown as fold induction compared to untreated cells (sample RLUs per mg of protein/
control RLUs per mg of protein)7SD. np˂0.05, nnp˂0.01, nnnp˂ 0.001.
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method following the manufacturer's instructions. Results are shown
as Fold induction compared to the reference sample7SD.
2.5. Western blot
Protein extracts were obtained by lysis in Igepal buffer (50 mM
Tris–HCl pH 8, 10 mM EDTA, 150 mM NaCl, 0.1% SDS, 1% Igepal)
with protease inhibitors (aprotinin, leupeptin and pepstatin at
10 μg/ml), and PMSF (phenyl-methylsulphonyl ﬂuoride, 0.5 mM).
Protein concentration was determined by the BCA method (Thermo
Scientiﬁc). Cell lysates were subjected to Western blot analysis using
conventional SDS-PAGE gel electrophoresis and protein transfer to
nitrocellulose ﬁlters. Membranes were incubated with the indicated
antibodies and developed by the enhanced chemiluminescence
system (Thermo Scientiﬁc). COX-2 and mPGES-1 protein expression
was detected using monoclonal antibodies (BD Transduction Labora-
tories and Cayman Chemical). Antibodies anti-LXRα, LXRβ and Egr-1
were purchased from Santa Cruz Biotechnology. As a loading control,
β-actin levels were determined with a speciﬁc antibody (Santa Cruz
Biotechnology).
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Fig. 2. LXR agonists induce transcriptional activation of target genes in macrophages. Cells were treated with LXR ligands TO901317 (TO) or GW3965 (GW) during 18 h (1 μM
in RAW264.7 and THP-1 cells; 0.5 μM in peritoneal macrophages) and mRNA levels of ABCA1 and ABCG1 were analyzed by standard or quantitative RT-PCR. For standard RT-
PCR, an aliquot of the ampliﬁed DNA was separated on an agarose gel and stained with ethidium bromide for qualitative comparison. GAPDH mRNA levels are shown as a
control of loading. mRNA levels analyzed by qRT-PCR are normalized to the expression of 18S rRNA. Results are shown as the mean of fold induction over the control
group7SD of three independent experiments performed in triplicate. nnnp˂0.001.
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Fig. 3. Inhibition of LPS-induced expression of pro-inﬂammatory genes by LXR ligands in macrophages. RAW264.7 cells were incubated with the LXR ligand GW3965 (GW,
1 μM) prior LPS stimulation (2 μg/ml) during 18 h. Expression of IL-6, IL-1β, MCP-1, COX-2 and mPGES-1 was analyzed by quantitative RT-PCR. Results were normalized to the
expression of 18S rRNA and shown as the mean of fold induction over the control group7SD of three independent experiments performed in triplicate. nnp˂0.01, nnnp˂0.001
compared to LPS-treated cells in the absence of ligand.
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2.6. Prostanoid determination
PGE2 and PGF2α levels were measured in culture supernatants
of RAW264.7 cells after the indicated treatments by competitive
immunoassay EIA kits (Cayman Chemical). Samples were analyzed
in triplicate following manufacturer's instructions.
2.7. Statistical analysis
Results are shown as the mean7SD of triplicate determinations
from at least two independent experiments. When a representative
experiment is shown, data are mean7SD of triplicate determina-
tions of this particular experiment. In these cases, equivalent results
were obtained in two or three independent experiments performed
in triplicate, as indicated in the ﬁgure legends. Statistical analysis
and calculation of P-values were performed by ANOVA followed by
Bonferroni's post-hoc test, using GraphPad Prism 5 software. Po
0.05 was considered statistically signiﬁcant.
3. Results
3.1. LXRE-dependent transcriptional activation by LXR and RXR
ligands in macrophages
LXRE-dependent transcriptional activation depends relies on the
binding of speciﬁc ligands to LXR/RXR heterodimers [1,4]. In order to
study LXR-dependent transcriptional activation in macrophages,
murine RAW264.7 and human THP-1 cell lines were transiently
transfected with the reporter vector LXRE-LUC, containing three
consensus binding sites for LXR upstream of a thymidine kinase
promoter [20]. As shown in Fig. 1A, LXR ligands TO901317 (TO) and
GW3965 (GW) efﬁciently induced transcription of the LXRE-luc
reporter in both cell lines. Transcriptional activation mediated by
TO and, to a minor extent, by the natural LXR ligand 25 hydro-
xycholesterol (25HC), increased in RAW264.7 cells that were co-
transfected with a LXRα expression plasmid (Fig. 1B). Treatment
with the RXR ligand 9cis-retinoic acid (9cisRA) also induced
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Fig. 4. Inhibition of LPS-induced expression of COX-2 by LXR ligands in macrophages. (A) and (B) RAW264.7 cells were incubated with the LXR ligands GW3965 (GW), TO901317
(TO) or 25 hidroxycholesterol (25HC), at the indicated concentration (0.1 to 1 μM), before LPS stimulation (2 μg/ml) during 18 h. COX-2 protein levels were studied byWestern blot
and mRNA expression levels were analyzed by quantitative RT-PCR. Protein levels of β-actin are shown as loading control. (C) THP-1 cells were treated with LXR ligands TO or GW
(1 μM) and peritoneal macrophages were treated with TO at the indicated doses (0.1 to 2.5 μM) and then stimulated with LPS. After 18 h, COX-2mRNA expressionwas analyzed by
quantitative RT-PCR. Results from quantitative RT-PCR are normalized to the endogenous expression of 18S rRNA and shown as the mean of fold induction over the control
group7SD of two independent experiments performed in triplicate. np˂0.05, nnp˂0.01, nnnp˂0.001 compared to LPS-treated cells in the absence of ligand.
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LXRE-dependent transcriptional activity in the absence and in the
presence of overexpressed RXRα. Maximal induction of LXRE-
dependent transactivation was observed upon combined treatment
with LXRα and RXRα ligands (Fig. 1B).
We next evaluated the effect of LXR ligands on the expression of
LXR target genes as the ATP-binding cassette transporter proteins
ABCA1 and ABCG1, by RT-PCR, in RAW264.7 and THP-1 cell lines as
well as in peritoneal macrophages. As shown in Fig. 2, mRNA levels
of ABCA1 and ABCG1 genes increased signiﬁcantly upon treatment
with the LXR ligands GW or TO in these cells.
3.2. LXR agonists reduce LPS-induced expression of COX-2 and
mPGES-1
In addition to promote transcriptional induction of genes involved
in lipid homeostasis, LXR activation has been shown to display
anti-inﬂammatory effects by repressing the expression of pro-
inﬂammatory genes [14,23–26]. Thus, we next analyzed the effect
of LXR activation on the expression of genes involved in inﬂamma-
tion such as the cytokines IL-6 and IL-1β, the chemokine MCP-1 and
the enzymes COX-2 and mPGES-1. As shown in Fig. 3, LXR activation
reduced substantially LPS-induced expression of these genes in
RAW264.7 macrophages.
Once assessed the potential anti-inﬂammatory effects of LXR
agonists in macrophages, we focused our studies on their effects
on the regulation of the expression of COX-2 and mPGES-1,
enzymes that play an essential role in the increase of prostanoid
synthesis upon macrophage activation. LXR natural ligands such as
25HC, and synthetic ones such as TO or GW, were able to reduce
LPS-induced expression of COX-2 at the protein and mRNA levels
in RAW264.7 cells in a dose-dependent manner (Fig. 4A and B).
These inhibitory effects of LXR ligands on COX-2 expression were
also observed in THP-1 cells and peritoneal macrophages (Fig. 4C).
As shown in Fig. 5A and B, LXR ligands were also able to reduce
LPS-mediated increase in mPGES-1 expression in macrophage/
monocyte-like cell lines and primary murine macrophages.
Both COX-2 and the terminal synthases involved in prostanoid
synthesis as mPGES-1 are tightly regulated, in such a way that
induction or inhibition of their expression inﬂuences the ﬁnal
balance of prostanoid production by macrophages, with a key role
in the inﬂammatory response [30,31]. In accordance with their
effect on diminishing LPS-induced COX-2 and mPGES-1 expres-
sion, LXR agonists severely impaired prostaglandin production by
activated RAW264.7 cells. As shown in Fig. 6, LXR activation highly
decreased the production of the COX-2/mPGES-1 dependent
production of prostaglandin PGE2. Increased production of PGF2α
in response to LPS was also reduced by LXR ligands.
3.3. Inhibition of LPS-induced COX-2 and mPGES-1 expression by
RXR agonists
LXRs form heterodimers with the obligate partner RXR, in such
a way that the LXR/RXR heterodimer can be activated by either
LXR or RXR agonists [1,4]. As shown in Fig. 1B, the RXR ligand
9cisRA was able to induce LXRE-dependent luciferase activity both
cooperating with LXR ligands as well as on its own, in RAW264.7
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macrophages. On the other hand, LXR activation did not affect
RXRE-dependent transcription that was efﬁciently induced by the
RXR ligands 9cisRA and SR11237 (SR) (Fig. 7). We next examined
the role of RXR activation on the LPS-induced expression of COX-2
and mPGES-1. Treatment with RXR ligands 9cisRA or SR led to a
signiﬁcant reduction in the activation of COX-2 expression in
LPS-treated RAW264.7 cells at the protein and mRNA levels, in a
dose-dependent manner (Fig. 8A and B). In primary macrophages
stimulated with LPS, RXR ligands inhibited COX-2 expression to a
similar extent as LXR ligands (Fig. 8B). Treatment of macrophages
with the RXR ligands 9cisRA or SR also produced a substantial
reduction in the LPS-induced expression of mPGES-1 in a dose-
dependent manner (Fig. 8C). Combination of 9cisRA with LXR
ligands promoted a mild but signiﬁcant increase in the inhibitory
effect on the induction COX-2 expression but not in the case of
mPGES-1. Maximal inhibitory effect in mPGES-1 mRNA levels
occurred in the presence of the RXR ligand 9cisRA (Fig. 8D).
3.4. LXR/RXR activation diminishes COX-2 and mPGES-1 promoter
activity
To further characterize the LXR/RXR mediated repression of COX-
2 and mPGES-1, transfection assays were carried out in THP-1 cells
using reporter plasmids including the promoter region of both
genes. LPS treatment induced luciferase activity of both promoters
and, as shown in Fig. 9, treatment with LXR or RXR agonists pro-
duced a signiﬁcant decrease in the induction of COX-2 and mPGES-1
promoter activity. These results suggested that the inhibitory effect
of LXR/RXR ligands occurred through interference at the tran-
scriptional level.
3.5. LXR/RXR activation interferes with the activity of NFκB and Egr-
1 transcription factors
Inhibition of the expression of pro-inﬂammatory genes by LXR/
RXR heterodimers has been proposed to take place by interference
with the activity of transcription factors. In this sense, different
studies have focused on the effects of LXR activation on NFκB
activity [14,23,27]. To test the effects of LXR/RXR ligands on NFκB
activity, THP-1 cells were transiently transfected with an NFκB-luc
reporter plasmid containing three copies of a consensus κB se-
quence, along with expression vectors for LXRα or RXRα. Upon
transfection, cells were activated with LPS, in the presence or
absence of LXR or RXR ligands. As shown in Fig. 10A, LXR/RXR
activation promoted a signiﬁcant reduction in the induction of
NFκB-luc activity by LPS.
In addition to NFκB, several transcription factors have been
shown to be involved in the LPS-mediated induction of these
enzymes in macrophages [34,44–46]. In this sense, we have
described the cooperation of Egr-1 and NF-κB as determinant for
PGE2 synthesis by macrophages in inﬂammatory processes, through
the coordinated regulation of COX-2 and mPGES-1 [33]. The effect of
LXR/RXR ligands on Egr-1 activity was analyzed in THP-1 cells
transfected with a construct containing two Egr-1 consensus-binding
sites inserted upstream of a prolactin minimal promoter (Egr1-luc).
LPS stimulation of RAW264.7 cells induced Egr1-luc mediated
luciferase activity. This induction was signiﬁcantly reduced upon
treatment with LXR or RXR ligands (Fig. 10B).
3.6. LXR/RXR activation interferes with LPS-induced expression of
Egr-1 in macrophages
To further analyze the interference of LXR/RXR ligands with Egr-1
activation, we next evaluated the expression of this transcription
factor in macrophages stimulated with LPS and treated with increas-
ing doses of the nuclear receptor agonists TO and 9cisRA. Western
Blot analysis showed an increase in Egr-1 protein levels in RAW264.7
cells treated for 18 h with LPS. Treatment with increasing doses of TO
or 9cisRA resulted in a dose dependent reduction of Egr-1 protein
levels (Fig. 11A). Similarly, induction of Egr-1 mRNA expression by
LPS, was decreased in RAW264.7 cells treated with the RXR ligands
9cisRA or SR (Fig. 11B).
As Egr-1 expression is rapidly induced upon LPS treatment in
macrophages, showing an increase that reaches the highest levels
after 1 h of treatment, we also assessed the effect of LXR/RXR
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1 cells were transfected with the reporter plasmid RXRE-luc. After transfection,
cells were treated with either RXR ligands 9cisRA and SR11237 (SR) or the LXR
ligand GW3965 (GW) at 2 μM for 18 h and then luciferase activity was measured in
cellular extracts. Results of a representative experiment of two performed are
shown as fold induction compared to untreated cells (sample RLUs per mg of
protein/control RLUs per mg of protein)7SD. np˂0.05.
P. Guillem-Llobat, M.A. Íñiguez / Prostaglandins, Leukotrienes and Essential Fatty Acids 96 (2015) 37–49 43
β-actin
COX-2
– 0.1 2.5 – 0.1 0.25 1 2.59cisRA
LPS
– 0.1 2.5 – 0.1 0.25 1 2.5SR
LPS
Peritoneal macrophages
LPS 
SR9cisRA TO- -
0
5
10
15
20
25
C
O
X-
2
re
la
tiv
e
m
R
N
A
le
ve
l
(fo
ld
in
du
ct
io
n)
-
- + + +
2.5 0.1
LPS
9cisRA (μM)
- - +
0.1 1 2.5-
0
50
100
150
C
O
X-
2
re
la
tiv
e
m
R
N
A
le
ve
l
(fo
ld
in
du
ct
io
n)
-
- + + +
2.5 0.1
LPS
SR (μM)
- - +
0.1 1 2.5-
0
20
40
60
80
100
120
2-X
OC
lev el
A
N
R
m
evital er
%
-
+ + +
+
LPS
TO
+
+ -
-9cisRA - + +
C
O
X-
2
level
A
N
R
m
evitaler
%
0
20
40
60
80
100
120
-
+ + +
+
LPS
GW
+
+ -
-9cisRA - + +
0
20
40
60
80
100
120
m
PG
ES
-1
level
A
N
R
m
ev ital er
%
-
+ + +
+
LPS
TO
+
+ -
-9cisRA - + +
ns
0
2
4
6
8
1-SE
GP
m
level
A
N
R
m
evitaler
)n oitcudni
dlof (
0
5
10
15
20
m
PG
ES
-1
re
la
tiv
e
m
R
N
A
le
ve
l
(fo
ld
in
du
ct
io
n)
-
- + + +
2.5 0.1
LPS
9cisRA (μM)
- - +
0.1 1 2.5- -
- + + +
1 0.1
LPS
SR (μM)
- - +
0.1 0.25 1-
Fig. 8. Inhibition of LPS-induced expression of COX-2 and mPGES-1 by RXR ligands. Cells were incubated with RXR ligands 9cis-retinoic acid (9cisRA) and SR11237 (SR) or
LXR ligands (TO901317 (TO) or GW3965 (GW) before LPS stimulation (2 μg/ml) during 18 h. (A) Analysis of COX-2 mRNA levels by quantitative RT-PCR in RAW264.7 cells
incubated with 9cisRA and SR11237 at the indicated concentration (0.1 to 2.5 μM) before LPS treatment. (B) Analysis of COX-2 protein levels by Western blot in RAW264.7
cells treated with 9cisRA and SR at different doses (0.1 to 2.5 μM). Murine peritoneal macrophages were treated with 1 μM of TO, 9cisRA or SR11237 prior to LPS stimulation.
β-actin protein levels are shown as a control. (C) mPGES-1 mRNA expression analysis by quantitative RT-PCR in LPS-stimulated (2 μg/ml) and RXR ligand-treated RAW264.7
cells (at the indicated concentration). (D) COX-2 and mPGES-1 mRNA levels were determined by quantitative RT-PCR in RAW264.7 cells treated with either the RXR ligand
9cisRA or the LXR ligands TO or GW, alone or in combination, before LPS stimulation. Results from representative experiments of at least two performed in triplicate are
normalized to 18S rRNA expression and shown as percentage of expression7SD, considering 100% that obtained in the LPS stimulated samples. Results from quantitative RT-
PCRs are normalized by 18S rRNA levels and shown as mean of fold induction over untreated cells7SD. np˂0.05, nnp˂0.01, nnnp˂0.001, (ns) not signiﬁcant.
P. Guillem-Llobat, M.A. Íñiguez / Prostaglandins, Leukotrienes and Essential Fatty Acids 96 (2015) 37–4944
ligands on EGR-1 expression by Western blot and RT-PCR after
short incubations with LPS (up to 2 h). As shown in Fig. 12A and B,
early induction of Egr-1 protein and mRNA levels was severely
impaired after treatment with LXR or RXR ligands.
4. Discussion
In addition to the well-known actions of LXRs in the regulation
of lipid homeostasis, increasing evidence supports a role of LXRs as
anti-inﬂammatory transcription factors through their antagonism
with the induction of pro-inﬂammatory genes [14–16,19]. In
this sense, various studies have clearly pointed out that LXRs play
a pivotal role in innate immunity modulating macrophage
activation. Ligand activation of these receptors modulates macro-
phage apoptosis [17,20,22] and negatively regulates expression of
pro-inﬂammatory genes in activated macrophages [14,23–26,47].
LXR receptor activation plays a key role in modulating the
function of macrophages on the regulation of cholesterol metabo-
lism by inducing the expression of various genes involved in
cholesterol homeostasis as apolipoprotein E and members of
the ABC transporter family [5–7,48]. Our studies conﬁrm that
LXR activation with speciﬁc ligands as TO901317, GW3965 or
25-hydroxycholesterol was able to induce transcriptional activat-
ion mediated by LXRE elements and the induction of LXR
target genes as ABCA1 and ABCG1 in the human and murine
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monocyte-macrophage cell lines RAW264.7 and THP-1, as well as in
mouse peritoneal macrophages. LXRs form permissive heterodi-
mers with RXR and thus can exert their regulatory effects on gene
expression in macrophages, upon activation by either LXR or RXR
ligands [1–4]. Accordingly, we found that both LXR ligands and RXR
agonists were able to induce gene expression through LXREs.
Moreover, combination of both types of ligands produced a sub-
stantial increase in such induction. In turn, over-expression of both
RXRα and LXRα receptors signiﬁcantly increased ligand-dependent
transcriptional activation in RAW264.7 cells.
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quantitative RT-PCR (B). Results from quantitative RT-PCRs are normalized by the expression of the rRNA 18S and shown as mean of fold induction over control7SD from
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We have also shown that, in addition to their ability to up-
regulate LXR-dependent expression of target genes in murine and
human macrophages, LXR ligands led to an inhibition of the LPS-
induced expression of pro-inﬂammatory genes such as IL-6, IL1-β
and MCP-1. Several reports have shown LXR-dependent negative
regulation of the induction of pro-inﬂammatory genes in response
to different stimuli in macrophages, including IL-6, MCP-1, iNOS
as well as enzymes involved in prostanoid production [14,23–25,
49,50]. Here, we have analyzed the effects of different LXR and RXR
ligands on the expression of COX-2 and mPGES-1 enzymes. Coordi-
nated induction of these genes is responsible for the increase in the
production of PGE2 that takes place in response to inﬂammatory
stimuli in different cell types, including activated macrophages
[33,35,51,52]. Induction of COX-2 and mPGES-1 transcriptional
activation in response to stimulation with LPS was reduced sig-
niﬁcantly by activation of LXR/RXR heterodimers. Consequently,
LXR-mediated inhibition of these two enzymes led to a decrease
in the production of PGE2 in these cells. Furthermore, although to a
lesser extent, a reduction in other prostanoids such as PGF2α was
detected in the supernatant of LPS-activated macrophages treated
with LXR agonists. Since there is no previous evidence about LXR-
mediated regulation of the expression of other terminal prostanoid
synthases, reduction in PGF2α synthesis could be a consequence of
the inhibition of COX-2 expression, which regulates the limiting step
in the conversion of arachidonic acid to PGH2, essential for prosta-
noid biosynthesis.
In addition to the previously reported anti-inﬂammatory effect
of LXR ligands, our results also support an anti-inﬂammatory role
of RXR ligands. To determine RXR-mediated effects, we have used
9cisRA as the RA stereoisomer with higher afﬁnity for RXRs [43].
As 9cisRA can also act through binding to RA receptors, we have
conﬁrmed the results obtained with the use of the speciﬁc RXR
agonist SR11237. This ligand allows the speciﬁc activation of RXR-
selective response pathways without inducing RAR-dependent
response pathways [53]. Treatment of LPS activated macrophages
with these RXR ligands resulted in a reduction of COX-2 and
mPGES-1 transcriptional induction similar to that observed with
LXR ligands. Recent reports have demonstrated the existence of an
RXR-selective signaling pathway, independent of heterodimeriza-
tion with other nuclear receptors in macrophages and able to
control innate inﬂammatory responses by up-regulating the tran-
scription of chemokine expression [54].
Most of the evidence about the anti-inﬂammatory effects of
nuclear receptor activation has been explained by the existence of a
mechanism of transrepression that results in the interference with
the activation of transcription factors implicated in the expression of
pro-inﬂammatory genes [47,55]. Thus, LXR-dependent transcrip-
tional repression is thought to occur, at least in part, by interference
with the pro-inﬂammatory transcription factor NFκB [14,23,27,56].
In agreement with that, we have shown that the LPS-induced
activity of NFκB, is reduced in the presence of LXR and RXR ligands.
In addition to NFκB, other transcription factors including Egr-1 are
known to participate in transcriptional induction of COX-2 and
mPGES-1 in response to LPS [32–35]. Our results show that, besides
interfering with NFκB-activation, LXR and RXR ligands modulate
Egr-1-mediated signaling. LXR and RXR agonists down regulated
induced expression of Egr-1 upon LPS-treatment in macrophages.
Moreover, Egr-1-dependent transcriptional activation was also
affected by these ligands, thus suggesting a role of LXR and RXR
signaling in the transrepression of Egr-1-dependent genes involved
in inﬂammation such as COX-2 and mPGES-1, but also other as
MCP-1, TNFα or IL-1β. Egr-1 expression is induced under pro-
inﬂammatory conditions and this transcription factor has been im-
plicated in the regulation of a wide range of genes that are involved
in macrophage responses [36,37,57,58]. Regulation of Egr-1 expres-
sion depends on signaling by mitogen-activated kinases (MAPK),
and on activation of other transcription factors such as NFκB [59,60].
In addition, a positive feedback mechanism for Egr-1 has been
recently identiﬁed [61]. Further work will be necessary to determine
if the inhibition of Egr-1 activation by LXR/RXR heterodimers takes
place by direct interference with the transcription factor, or indir-
ectly, through inhibition of other factors involved in Egr-1 expres-
sion, as NFκB. Nevertheless, considering the fact that this tran-
scription factor is involved in the regulation of a variety of genes
involved in inﬂammatory processes, LXR/RXR-mediated interference
with Egr-1 could contribute to explain anti-inﬂammatory actions of
drugs targeting these nuclear receptors.
The discoveries of LXR-regulated inﬂammatory pathways have
open new promises for these receptors and their target genes for
therapeutic intervention in human diseases. LXR activation in
cellular and animal models has proven to have anti-inﬂammatory
effects, reducing inﬂammatory responses in several diseases with an
important inﬂammatory component, including rheumatoid arthritis,
atherosclerosis, Alzheimer0s disease and skin disorders [2,62]. The
dual role of LXRs as cholesterol sensors and regulators of inﬂamma-
tion has been demonstrated to be essential for the attenuation
of atherosclerotic plaque development by LXR agonists in animal
models of atherosclerosis [17–19,63]. However, these treatments
also promoted an LXR-mediated increase in lipogenesis in the liver,
resulting in increased levels of serum and hepatic triglycerides. In
order to overcome these undesirable effects of LXR activation in the
liver after the systemic administration of agonists, new strategies for
pharmacological intervention are currently aimed to increase the
selectivity regarding LXR subtype and pathway, as well as the cell
type or tissue where they exert their actions. New generation of
compounds as the intestine-speciﬁc agonist GW6340 retain the
capacity to modulate cholesterol levels, avoiding liver-related side
effects [64]. The ﬁrst LXR ligand of this new class of agonists used in
a phase I clinical trial was the compound LXR-623. This LXR agonist
produced an increase in the expression of target genes involved
in reverse cholesterol transport in healthy volunteers without
increased hepatic triglyceridaemia when administered at low doses
[65]. Unfortunately, these clinical trials were discontinued because
of adverse neurological side effects. Although similar adverse effects
have not been reported for other LXR agonists, some other LXR
ligands that have entered in clinical trials have also had limited
success [66]. Thus, both increase in the knowledge on new LXR/RXR
target genes and pathways, on their potential contribution to
pathophysiology, as well as the development of safer and therapeu-
tically efﬁcacious drugs targeting these receptors, will contribute to
deﬁne their potential as drugs for therapeutic intervention.
In this context, our results provide new evidence on the anti-
inﬂammatory actions of LXR, but also RXR activation, through the
regulation of the LPS-mediated transcriptional induction of proinﬂam-
matory genes in macrophages. Thus, it will be therefore relevant to
achieve a deeper understanding of the possible differences or the
common traits of LXR and RXR-mediated anti-inﬂammatory effects in
different cell types or tissues in both pathological and physiological
conditions. These results contribute to the overall knowledge on the
LXR-mediated transrepression effects by furnishing new data on the
interference of LXR and RXR agonists with the Egr-1-dependent sig-
naling.
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